Press Releases

Date Title and Summary Additional Formats
Toggle Summary Concert Pharmaceuticals Reports Positive Results from Phase 1 Studies Evaluating CTP-692 in Healthy Volunteers
The Company Expects to Initiate a Phase 2 Trial in Patients with Schizophrenia in the Fourth Quarter of 2019 LEXINGTON, Mass. --(BUSINESS WIRE)--Jun. 12, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported positive results from two studies in its Phase 1 program evaluating CTP-692, a
View HTML
Toggle Summary Concert Pharmaceuticals Completes Enrollment in Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata
LEXINGTON, Mass. --(BUSINESS WIRE)--Jun. 5, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.
View HTML
Toggle Summary Concert Pharmaceuticals Announces Initiation of New Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata
LEXINGTON, Mass. --(BUSINESS WIRE)--May 16, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated a second open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.
View HTML
Toggle Summary Concert Pharmaceuticals to Present at Upcoming Investor Conferences
LEXINGTON, Mass. --(BUSINESS WIRE)--May 14, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming investor conferences: The UBS Global Healthcare Conference on May 21, 2019 at 10:00 a.m.
View HTML
Toggle Summary Concert Pharmaceuticals Reports First Quarter 2019 Financial Results
Conference Call Scheduled Today at 8:30 a.m. ET LEXINGTON, Mass. --(BUSINESS WIRE)--May 2, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2019. “The progress we are making to advance our pipeline positions us for a series of significant
View HTML
Toggle Summary Concert Pharmaceuticals Names Jesper Høiland to its Board of Directors
LEXINGTON, Mass. --(BUSINESS WIRE)--Apr. 29, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) announced today that Jesper Høiland has been appointed to its Board of Directors and will serve as a member of its Compensation Committee, effective immediately.
View HTML
Toggle Summary Concert Pharmaceuticals to Report First Quarter 2019 Financial Results on May 2, 2019
LEXINGTON, Mass. --(BUSINESS WIRE)--Apr. 25, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2019 financial results on Thursday, May 2, 2019 , before the U.S. financial markets open. The Company will host a conference call and webcast at
View HTML
Toggle Summary Concert Pharmaceuticals to Present CTP-543 Phase 2 Interim Data in Alopecia Areata at 2019 World Congress for Hair Research Annual Meeting
LEXINGTON, Mass. --(BUSINESS WIRE)--Apr. 11, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata will be presented in a poster presentation and a sponsored lecture at the 11 th Annual World Congress for
View HTML
Toggle Summary Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia
LEXINGTON, Mass. --(BUSINESS WIRE)--Apr. 10, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated an additional trial in the Phase 1 program evaluating CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for
View HTML
Toggle Summary Concert Pharmaceuticals Announces Decision from Patent Trial and Appeal Board in IPR Proceeding
LEXINGTON, Mass. --(BUSINESS WIRE)--Apr. 8, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a final written decision in connection with the inter partes review (IPR) of U.S.
View HTML